ArticleArhiv za higijenu rada i toksikologiju2025
Chlorogenic acid protects against cisplatin-induced testicular damage: a biochemical and histological study.
Article in Arhiv za higijenu rada i toksikologiju, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The protective effects of naringin against cisplatin-induced pulmonary toxicity in rats: Insights into the modulation of ER stress and SIRT1/Nrf2 pathway.BMC complementary medicine and therapies · 2026Article
- Protection byPharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the adverse effects of cisplatin (CIS) treatment is its reproductive toxicity, which limits its clinical use in male patients. The aim of our study was to investigate the potential protective effects and mechanisms of chlorogenic acid (CHA), a well-known antioxidant and anti-inflammatory polyphenol, in a CIS-induced testicular toxicity model. To this end we divided 30 Sprague-Dawley rats into five groups: control and four groups receiving either CHA alone (3 mg/kg), CIS alone (5 mg/kg), or their weaker and stronger combinations: CIS+CHA (1.5 mg/kg) and CIS+CHA (3 mg/kg), respectively. In the combination groups the rats first received a single 5 mg/kg dose of CIS, followed by either 1.5 or 3 mg/kg of CHA administered intraperitoneally for three consecutive days. Testicular tissues were harvested on the fifth day of the experiment. The level of testicular oxidative stress and inflammation induced by CIS and the histopathological changes observed were restored to normal following treatment with both doses of CHA. Furthermore, treatment with CHA led to the regeneration of Nrf2 and HO-1 levels, which had been suppressed by CIS. Consequently, the levels of endoplasmic reticulum stress and apoptosis were reduced. These findings indicate that CHA may counter the reproductive toxicity of CIS and may therefore serve as its add-on in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.